FATE
Fate Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.48
+2.48%Year over year
Reported trailing growth
- Revenue
- -23.4%
- EBITDA
- +24.4%
- EBIT
- +30.6%
- EPS
- +27.6%
- Free cash flow
- +11.0%
- Operating cash flow
- +11.8%
Forward estimates
Based on analyst estimates
- Revenue
- -34.4%
- EBITDA
- -5.2%
- EPS
- -5.6%
Three-year CAGR
- Revenue
- -59.0%
- EBITDA
- +28.1%
- EBIT
- +29.8%
- Net income
- +26.8%
- EPS
- +29.9%
- Free cash flow
- +9.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026